RNA Quote, Financials, Valuation and Earnings

Dyne Therapeutics has a net margin of -7360.01% compared to Avidity Biosciences's net margin of --. Avidity Biosciences's return on equity of -29.26% beat Dyne Therapeutics's return on equity of --.

Avidity Biosciences has a consensus price target of $68.31, signalling upside risk potential of 133.07%. On the other hand Dyne Therapeutics has an analysts' consensus of $45.21 which suggests that it could grow by 317.96%. Given that Dyne Therapeutics has higher upside potential than Avidity Biosciences, analysts believe Dyne Therapeutics is more attractive than Avidity Biosciences.

Avidity Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dyne Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Avidity Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dyne Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences pays -- of its earnings as a dividend. Dyne Therapeutics pays out -- of its earnings as a dividend.

Avidity Biosciences quarterly revenues are $1.6M, which are larger than Dyne Therapeutics quarterly revenues of --. Avidity Biosciences's net income of -$115.8M is lower than Dyne Therapeutics's net income of -$115.4M. Notably, Avidity Biosciences's price-to-earnings ratio is -- while Dyne Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences is 400.69x versus -- for Dyne Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics has a net margin of -7360.01% compared to Avidity Biosciences's net margin of -687.61%. Avidity Biosciences's return on equity of -29.26% beat Intellia Therapeutics's return on equity of -56.9%.

Avidity Biosciences has a consensus price target of $68.31, signalling upside risk potential of 133.07%. On the other hand Intellia Therapeutics has an analysts' consensus of $37.30 which suggests that it could grow by 305.4%. Given that Intellia Therapeutics has higher upside potential than Avidity Biosciences, analysts believe Intellia Therapeutics is more attractive than Avidity Biosciences.

Avidity Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intellia Therapeutics has a beta of 2.141, suggesting its more volatile than the S&P 500 by 114.144%.

Avidity Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences pays -- of its earnings as a dividend. Intellia Therapeutics pays out -- of its earnings as a dividend.

Avidity Biosciences quarterly revenues are $1.6M, which are smaller than Intellia Therapeutics quarterly revenues of $16.6M. Avidity Biosciences's net income of -$115.8M is lower than Intellia Therapeutics's net income of -$114.3M. Notably, Avidity Biosciences's price-to-earnings ratio is -- while Intellia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences is 400.69x versus 20.36x for Intellia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regenxbio has a net margin of -7360.01% compared to Avidity Biosciences's net margin of 6.83%. Avidity Biosciences's return on equity of -29.26% beat Regenxbio's return on equity of -50.09%.

Avidity Biosciences has a consensus price target of $68.31, signalling upside risk potential of 133.07%. On the other hand Regenxbio has an analysts' consensus of $31.75 which suggests that it could grow by 276.63%. Given that Regenxbio has higher upside potential than Avidity Biosciences, analysts believe Regenxbio is more attractive than Avidity Biosciences.

Avidity Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regenxbio has a beta of 1.089, suggesting its more volatile than the S&P 500 by 8.891%.

Avidity Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

Avidity Biosciences quarterly revenues are $1.6M, which are smaller than Regenxbio quarterly revenues of $89M. Avidity Biosciences's net income of -$115.8M is lower than Regenxbio's net income of $6.1M. Notably, Avidity Biosciences's price-to-earnings ratio is -- while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences is 400.69x versus 2.74x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -7360.01% compared to Avidity Biosciences's net margin of -60.08%. Avidity Biosciences's return on equity of -29.26% beat Sarepta Therapeutics's return on equity of -20.94%.

Avidity Biosciences has a consensus price target of $68.31, signalling upside risk potential of 133.07%. On the other hand Sarepta Therapeutics has an analysts' consensus of $48.04 which suggests that it could grow by 139.24%. Given that Sarepta Therapeutics has higher upside potential than Avidity Biosciences, analysts believe Sarepta Therapeutics is more attractive than Avidity Biosciences.

Avidity Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.609, suggesting its less volatile than the S&P 500 by 39.15%.

Avidity Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Avidity Biosciences quarterly revenues are $1.6M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Avidity Biosciences's net income of -$115.8M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Avidity Biosciences's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences is 400.69x versus 1.00x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.